191 related articles for article (PubMed ID: 11019716)
1. Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
Fintel DJ; Ledley GS
Clin Cardiol; 2000 Sep; 23 Suppl 5(Suppl 5):V1-12. PubMed ID: 11019716
[TBL] [Abstract][Full Text] [Related]
2. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
[TBL] [Abstract][Full Text] [Related]
3. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
Zeymer U
Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
[TBL] [Abstract][Full Text] [Related]
4. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
[TBL] [Abstract][Full Text] [Related]
6. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA
Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
[TBL] [Abstract][Full Text] [Related]
9. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
11. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
[TBL] [Abstract][Full Text] [Related]
12. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW; Berkowitz SD; Sparapani R; Tuttle R; Kleiman NS; Berdan LG; Lincoff AM; Deckers J; Diaz R; Karsch KR; Gretler D; Kitt M; Simoons M; Topol EJ; Califf RM; Harrington RA
Circulation; 1999 Jun; 99(22):2892-900. PubMed ID: 10359733
[TBL] [Abstract][Full Text] [Related]
14. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
15. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
[TBL] [Abstract][Full Text] [Related]
16. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
17. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.
Cannon CP
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):43S-48S. PubMed ID: 12644340
[TBL] [Abstract][Full Text] [Related]
18. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
20. [Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment].
Mazaev AA; Naĭmushin IaA; Ruda MIa
Kardiologiia; 2006; 46(3):49-55. PubMed ID: 16710256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
